HomeCompareINT vs ABBV

INT vs ABBV: Dividend Comparison 2026

INT yields 2.31% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 INT wins by $8.50M in total portfolio value· pulled ahead in Year 4
10 years
INT
INT
● Live price
2.31%
Share price
$24.26
Annual div
$0.56
5Y div CAGR
83.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.61M
Annual income
$7,209,581.52
Full INT calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — INT vs ABBV

📍 INT pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodINTABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, INT + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
INT pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

INT
Annual income on $10K today (after 15% tax)
$196.21/yr
After 10yr DRIP, annual income (after tax)
$6,128,144.29/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, INT beats the other by $6,106,277.42/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of INT + ABBV for your $10,000?

INT: 50%ABBV: 50%
100% ABBV50/50100% INT
Portfolio after 10yr
$4.36M
Annual income
$3,617,653.62/yr
Blended yield
83.06%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

INT
Analyst Ratings
4
Buy
3
Hold
1
Sell
Consensus: Buy
Altman Z
6.5
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

INT buys
0
ABBV buys
0
No recent congressional trades found for INT or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricINTABBV
Forward yield2.31%3.12%
Annual dividend / share$0.56$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR83.8%40.6%
Portfolio after 10y$8.61M$104.7K
Annual income after 10y$7,209,581.52$25,725.73
Total dividends collected$8.47M$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: INT vs ABBV ($10,000, DRIP)

YearINT PortfolioINT Income/yrABBV PortfolioABBV Income/yrGap
1$11,124$424.27$11,559$438.51$435.00ABBV
2$12,714$810.73$13,494$640.86$780.00ABBV
3$15,195$1,591.62$15,951$945.97$756.00ABBV
4← crossover$19,527$3,267.66$19,152$1,413.89+$375.00INT
5$28,106$7,213.01$23,443$2,146.38+$4.7KINT
6$47,908$17,834.36$29,391$3,321.96+$18.5KINT
7$103,480$52,218.42$37,948$5,265.87+$65.5KINT
8$304,470$193,745.87$50,795$8,596.74+$253.7KINT
9$1,305,004$979,221.08$71,034$14,549.41+$1.23MINT
10$8,605,936$7,209,581.52$104,715$25,725.73+$8.50MINT

INT vs ABBV: Complete Analysis 2026

INTStock

World Fuel Services Corporation engages in the distribution of fuel and related products and services in the aviation, marine and land transportation industries worldwide. Its Aviation segment supplies fuel and related products and services to commercial airlines, second and third tier airlines, cargo carriers, regional and low-cost carriers, airports, fixed based operators, corporate fleets, fractional operators, private aircraft, the U.S., foreign governments, intergovernmental organizations, and military customers. This segment also offers fuel management, price risk management, ground handling, dispatch services and trip planning services, such as flight planning and scheduling, weather reports and overflight permits. Its Land segment offers fuel, heating oil, propane, natural gas, lubricants and related products and services to petroleum distributors and retail petroleum operators, as well as industrial, commercial, residential and government customers. This segment also offers management services for procuring fuel and price risk management; advisory and fulfillment solutions related to power, natural gas and other energy products; consulting, renewable fuel products, carbon management and renewable energy solutions and card payment solutions; and transaction management and commercial payment programs. Its Marine segment markets fuel, lubricants and related products and services to international container and tanker fleets, commercial cruise lines, yachts and time charter operators, offshore rig owners and operators, the U.S., foreign governments, and other fuel suppliers. Its marine fuel-related services include management services to procure fuel, cost control, quality control, and claims management services. This segment also engages in the fueling of vessels, transportation and delivery of fuel and fuel-related products. World Fuel Services Corporation was incorporated in 1984 and is headquartered in Miami, Florida.

Full INT Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this INT vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

INT vs SCHDINT vs JEPIINT vs OINT vs KOINT vs MAININT vs JNJINT vs MRKINT vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.